title: Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years.
abstract: OBJECTIVE
  To evaluate the effect of bone marrow transplantation in children with Hunter syndrome.
  
  
  METHODS
  Eight boys received a bone marrow graft between the ages of 3 and 16 years from 1990 to 2000. In 6 cases, the donor was a sibling with identical HLA status, in 1 case an unrelated donor with HLA-compatible, and in 1 case a mismatched unrelated donor. A complete multidisciplinary evaluation was performed yearly.
  
  
  RESULTS
  Successful engraftment was achieved in all patients, with the proportion of donor cells reaching > or =95% 1 month after transplantation in all patients. Patients have been followed from between 7 and 17 years and all are still alive, except for 1 boy who died at the age of 10 from unrelated causes. Cardiovascular abnormalities stabilized in all patients, hepatosplenomegaly resolved, and joint stiffness improved, Perceptual hearing defects remained stable, and transmission hearing defects improved. Only 1 child required subsequent surgery to correct kyphosis. Neuropsychological outcome was variable and appeared to be related to the severity of the syndrome.
  
  
  CONCLUSIONS
  Bone marrow transplantation is effective on the no neuropsychological symptoms of Hunter disease.
authors.affiliation: Reference Center of Metabolic Disease, Hospices Civils de Lyon, France. nathalie.guffon@chu-lyon.fr
authors.forename: Nathalie
authors.initials: N
authors.lastname: Guffon
authors.forename: Yves
authors.initials: Y
authors.lastname: Bertrand
authors.forename: Isabelle
authors.initials: I
authors.lastname: Forest
authors.forename: Alain
authors.initials: A
authors.lastname: Fouilhoux
authors.forename: Roseline
authors.initials: R
authors.lastname: Froissart
mesh_terms: D000293:Adolescent; D001827:Body Height; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D018450:Disease Progression; D005500:Follow-Up Studies; D006025:Glycosaminoglycans / Q000652:urine; D006085:Graft Survival; D006351:Heart Valves / Q000002:abnormalities; D006529:Hepatomegaly / Q000628:therapy; D006801:Humans; D007066:Iduronate Sulfatase / Q000378:metabolism; D007361:Intelligence Tests; D007592:Joint Diseases / Q000628:therapy; D007962:Leukocytes / Q000378:metabolism; D008297:Male; D051346:Mobility Limitation; D016532:Mucopolysaccharidosis II / Q000523:psychology / Q000601:surgery*; D017063:Outcome Assessment, Health Care; D012917:Social Adjustment; D013163:Splenomegaly / Q000628:therapy; D014019:Tissue Donors
chemical_list: D006025:Glycosaminoglycans; D007066:Iduronate Sulfatase